The Impact of Sickle Cell Disease Severity on HRQOL and Economic OutcomesApril 1st 2021
Disease severity was strongly associated with health-related quality of life, moderately associated with use of disability insurance, and weakly associated with household income for patients with sickle cell disease.
Lenacapavir Against HIV Demonstrates Ongoing PotentialMarch 16th 2021
The safety and effectiveness of the long-acting agent is backed by data from trials of the drug among treatment-experienced individuals living with HIV-1 whose viral load is on the rise due to other regimens failing. Investigation continues among these patients, as well as treatment-naive patients.
Report Describes Case of Improved Outcome in MM With Personalized MedicineMarch 6th 2021
Researchers describe the case of an older patient who underwent myeloma drug sensitivity testing as part of an effort to identify the therapies most likely to produce a response in this difficult-to-treat population.
Marrow Lymphocyte Patterns After ASCT May Have Prognostic Value in MMMarch 5th 2021
Patients with multiple myeloma (MM) often relapse over time despite initially achieving a complete response without minimal residual disease following induction treatment, leaving questions about changes in the immune system and the prognosis of the disease.
Trial of Anti-BCMA ide-cel for RRMM Leads to Undetectable Disease in 33% of PatientsFebruary 27th 2021
More than 2 years after treatment, some of the patients with relapsed/refractory multiple myeloma have yet to see a relapse. An FDA decision on the therapy is expected within a month.
Sustained MRD Negativity Predictive of Long-term Outcomes in RRMMFebruary 16th 2021
Sustained minimal residual disease (MRD) negativity may predict long-term outcomes in relapsed/refractory multiple myeloma (RRMM), and daratumumab-based combinations show higher rates of sustained MRD negativity compared with the standard of care.
Carfilzomib Improves Renal Response Compared With Bortezomib in RRMMFebruary 12th 2021
Carfilzomib-dexamethasone improved renal overall and complete response in patients with relapsed or refractory multiple myeloma (RRMM) compared with a regimen of bortezomib-dexamethasone in a real-world study.
What We’re Reading: EUA for Lilly’s Combination Treatment; COVID-19 Billing Waivers; Convalescent Plasma Indication UpdatedFebruary 10th 2021
The FDA issues an emergency use authorization (EUA) for Eli Lilly’s coronavirus disease 2019 (COVID-19) treatment; insurance waivers for COVID-19–related costs are starting to expire; new data update convalescent plasma’s indication.
Higher Mortality Seen Among HSCT Recipients Who Contract COVID-19January 20th 2021
Recipients of hematopoietic stem-cell transplantation (HSCT) who develop coronavirus disease 2019 (COVID-19) may be predisposed to a greater mortality rate if they meet certain disease criteria.
Risk Factors for Increased Mortality Among Patients With MM, COVID-19 IdentifiedJanuary 7th 2021
Age, renal disease, and suboptimal myeloma control were among the many factors identified in a recent study as increasing the risk of death from coronavirus disease 2019 (COVID-19) for patients being treated for multiple myeloma (MM).
Dr Robert Massie: Untreated Pooled Plasma Enabled Unchecked Virus TransmissionJanuary 5th 2021
Decades ago, companies refused to heat-treat their blood products, which resulted in pooled plasma, among others, enabling many viruses to be transmitted, noted Robert K. Massie Jr, PhD, MA, of the Society for Progress.
Metabolic Biomarkers Could Predict Prognosis, Treatment Outcomes in MMDecember 30th 2020
New research shows metabolic biomarkers could be meaningful tools for predicting treatment outcomes in patients, based on a comparison of biomarkers, clinical characteristics, and therapeutic efficacy.